Specifically, patients with non-oncogene addicted, stage IV NSCLC—both SqCC and non-SqCC—are suitable for ICIs treatment, alone or in combination with chemotherapy, depending on whether PD-L1 expression assessed on at least 100 tumor cells (TCs) is greater than 50% or equal and/or greater than 1%, respectively [4]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.